Copeptin is increased in resistant hypertension

Journal of Hypertension

Volumn 34, Issue 12, 2016, Pages 2458-2464

  Mendes, Margarida ^a   Dubourg, Julie ^b   Blanchard, Anne ^b,c,d   Bergerot, Damien ^d   Courand, Pierre Yves ^a,b   Forni, Valentina ^b   Frank, Michael ^e   Bobrie, Guillaume ^b   Menard, Joel ^b,c   Azizi, Michel ^b,c,d  

^a Dr Rui Adriano de Freitas Health Centre   (Portugal)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d INSERM   (France)

^e Fédération des hôpitaux de polyhandicap et multihandicap hôpital San Salvadour   (France)

Author keywords

Brain renin angiotensin system; Copeptin; Essential resistant hypertension; Vasopressin

Indexed keywords

AMILORIDE; AMLODIPINE; BISOPROLOL; COPEPTIN; FUROSEMIDE; HYDROCHLOROTHIAZIDE; IRBESARTAN; RAMIPRIL; SPIRONOLACTONE; ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; BIPHENYL DERIVATIVE; DIURETIC AGENT; GLYCOPEPTIDE; TETRAZOLE DERIVATIVE; VASOPRESSIN DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CLINICAL TRIAL (TOPIC); FEMALE; GENDER; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHRON; PLASMA OSMOLALITY; POST HOC ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESISTANT HYPERTENSION; URINE OSMOLALITY; BLOOD; COMPARATIVE STUDY; CORONARY VASOSPASM; DRUG EFFECTS; HYPERTENSION; MIDDLE AGED; OSMOLARITY; PATHOPHYSIOLOGY; SEX DIFFERENCE;

ADULT; AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BIOMARKERS; BIPHENYL COMPOUNDS; BLOOD PRESSURE; CORONARY VASOSPASM; DIURETICS; FEMALE; GLOMERULAR FILTRATION RATE; GLYCOPEPTIDES; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; NEPHRONS; OSMOLAR CONCENTRATION; RENIN-ANGIOTENSIN SYSTEM; SEX FACTORS; TETRAZOLES; VASOPRESSINS;

EID: 84991481643     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000001106     Document Type: Article

References (26)

1. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: Diagnosis, evaluation, and treatment: A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117: E510-e526.
2. Fagard RH. Resistant hypertension. Heart 2012; 98: 254-261.
3. Judd E, Calhoun DA. Apparent and true resistant hypertension: Definition, prevalence and outcomes. J Hum Hypertens 2014; 28: 463-468.
4. Cuspidi C, Macca G, Sampieri L, Michev I, Salerno M, Fusi V, et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens 2001; 19: 2063-2070.
5. Weber MA, Black H, Bakris G, Krum H, Linas S, Weiss R, et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: A randomised, doubleblind, placebo-controlled trial. Lancet 2009; 374: 1423-1431.
6. Azizi M, Perdrix L, Bobrie G, Frank M, Chatellier G, Menard J, et al. Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension. J Hypertens 2014; 32: 2038-2044.
7. Bobrie G, Frank M, Azizi M, Peyrard S, Boutouyrie P, Chatellier G, et al. Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: A prospective, randomized, open blinded endpoint study. J Hypertens 2012; 30: 1656-1664.
8. Mohring J, Mohring B, Petri M, Haack D. Is vasopressin involved in the pathogenesis of malignant desoxycorticosterone hypertension in rats? Lancet 1976; 1: 170-173.
9. Padfield PL, Brown JJ, Lever AF, Morton JJ, Robertson JI. Changes of vasopressin in hypertension: Cause or effect? Lancet 1976; 1: 1255-1257.
10. Thibonnier M, Sassano P, Daufresne S, Corvol P, Menard J. Osmoregulation and renal effects of vasopressin in normal and mildly hypertensive subjects. Kidney Int 1984; 25: 411-415.
11. Ando T, Shimamoto K, Nakahashi Y, Nishitani T, Hosoda S, Ishida H, et al. Plasma antidiuretic hormone levels in patients with normal and low renin essential hypertension, and secondary hypertension. Endocrinol Jpn 1983; 30: 567-570.
12. Thibonnier MJ, Marchetti JP, Corvol PL, Menard JE, Milliez P. Advantages and drawbacks of AVP radioimmunoassay in plasma and urine of normal subjects. Horm Metab Res 1981; 13: 300-301.
13. Morgenthaler NG, Struck J, Jochberger S, Dunser MW. Copeptin: Clinical use of a new biomarker. Trends Endocrinol Metab 2008; 19: 43-49.
14. Nogueira-Silva L, Blanchard A, Curis E, Lorthioir A, Zhygalina V, Bergerot D, et al. Deciphering the role of vasopressin in primary aldosteronism. J Clin Endocrinol Metab 2015; 100: 3297-3303.
15. Blanchard A, Steichen O, De Mota N, Curis E, Gauci C, Frank M, et al. An abnormal apelin/vasopressin balance may contribute to water retention in patients with the syndrome of inappropriate antidiuretic hormone (SIADH) and heart failure. J Clin Endocrinol Metab 2013; 98: 2084-2089.
16. Ettema EM, Kuipers J, Assa S, Bakker SJ, Groen H, Westerhuis R, et al. Changes in plasma copeptin levels during hemodialysis: Are the physiological stimuli active in hemodialysis patients? PLoS One 2015; 10: E0127116.
17. Szinnai G, Morgenthaler NG, Berneis K, Struck J, Muller B, Keller U, et al. Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects. J Clin Endocrinol Metab 2007; 92: 3973-3978.
18. Reaux A, Fournie-Zaluski MC, Llorens-Cortes C. Angiotensin III: A central regulator of vasopressin release and blood pressure. Trends Endocrinol Metab 2001; 12: 157-162.
19. Schrier RW, Berl T, Anderson RJ. Osmotic and nonosmotic control of vasopressin release. Am J Physiol 1979; 236: F321-F332.
20. Holmes CL, Patel BM, Russell JA, Walley KR. Physiology of vasopressin relevant to management of septic shock. Chest 2001; 120: 989-1002.
21. Adler SM, Verbalis JG. Disorders of body water homeostasis in critical illness. Endocrinol Metab Clin North Am 2006; 35: 873-894.
22. Grobe JL, Grobe CL, Beltz TG, Westphal SG, Morgan DA, Xu D, et al. The brain Renin-angiotensin system controls divergent efferent mechanisms to regulate fluid and energy balance. Cell Metab 2010; 12: 431-442.
23. Hasser EM, Cunningham JT, Sullivan MJ, Curtis KS, Blaine EH, Hay M. Area postrema and sympathetic nervous system effects of vasopressin and angiotensin II. Clin Exp Pharmacol Physiol 2000; 27: 432-436.
24. Ufnal M, Skrzypecki J. Blood borne hormones in a cross-talk between peripheral and brain mechanisms regulating blood pressure, the role of circumventricular organs. Neuropeptides 2014; 48: 65-73.
25. Alnima T, de Leeuw PW, Kroon AA. Baropacing as a new option for treatment of resistant hypertension. Eur J Pharmacol 2015; 763: 23-27.
26. Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: Results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol 2011; 58: 765-773.